title: Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates.
abstract: The competition between endogenous transmitters and radiolabeled ligands for in vivo binding to neuroreceptors might provide a method to measure endogenous transmitter release in the living human brain with noninvasive techniques such as positron emission tomography (PET) or single photon emission computerized tomography (SPECT). In this study, we validated the measure of amphetamine-induced dopamine release with SPECT in nonhuman primates. Microdialysis experiments were conducted to establish the dose-response curve of amphetamine-induced dopamine release and to document how pretreatment with the dopamine depleter alpha-methyl-para-tyrosine (alpha MPT) affects this response. SPECT experiments were performed with two iodinated benzamides, [123I]IBZM and [123I]IBF, under sustained equilibrium condition. Both radio-tracers are specific D2 antagonists, but the affinity of [123I]IBZM (KD-0.4 nM) is lower than that of [123I]IBF (KD 0.1 nM). With both tracers, we observed a prolonged reduction in binding to D2 receptors following amphetamine injection. [123I]IBZM binding to D2 receptors was more affected than [123I]IBF by high doses of amphetamine, indicating that a lower affinity increases the vulnerability of a tracer to endogenous competition. With [123I]IBZM, we observed an excellent correlation between reduction of D2 receptor binding measured with SPECT and peak dopamine release measured with microdialysis after various doses of amphetamine. Pretreatment with alpha MPT significantly reduced the effect of amphetamine on [123I]IBZM binding to D2 receptors, confirming that this effect was mediated by intrasynaptic dopamine release. Together, these results validate the use of this SPECT paradigm as a noninvasive measurement of intrasynaptic dopamine release in the living brain.
authors.affiliation: Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06516, USA.
authors.forename: M
authors.initials: M
authors.lastname: Laruelle
authors.forename: R N
authors.initials: RN
authors.lastname: Iyer
authors.forename: M S
authors.initials: MS
authors.lastname: al-Tikriti
authors.forename: Y
authors.initials: Y
authors.lastname: Zea-Ponce
authors.forename: R
authors.initials: R
authors.lastname: Malison
authors.forename: S S
authors.initials: SS
authors.lastname: Zoghbi
authors.forename: R M
authors.initials: RM
authors.lastname: Baldwin
authors.forename: H F
authors.initials: HF
authors.lastname: Kung
authors.forename: D S
authors.initials: DS
authors.lastname: Charney
authors.forename: P B
authors.initials: PB
authors.lastname: Hoffer
authors.forename: R B
authors.initials: RB
authors.lastname: Innis
authors.forename: C W
authors.initials: CW
authors.lastname: Bradberry
mesh_terms: D000661:Amphetamine / Q000494:pharmacology*; D000818:Animals; D001921:Brain / Q000000981:diagnostic imaging / Q000187:drug effects*; D004298:Dopamine / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D008251:Macaca; D008297:Male; D017551:Microdialysis; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D000661:Amphetamine; D004298:Dopamine